Precision Biosciences Inc (DTIL) — 8-K Filings

8-K Filings (21)

• 8-K Filing — Nov 12, 2025
• Precision BioSciences Files 8-K — Nov 10, 2025 Risk: low
  On November 10, 2025, Precision BioSciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial State
• Precision BioSciences Announces Board and Executive Changes — Sep 2, 2025 Risk: medium
  Precision BioSciences, Inc. announced on August 26, 2025, changes in its board and executive compensation. The filing details the departure of certain officers
• Precision BioSciences Files 8-K — Aug 6, 2025 Risk: low
  On August 6, 2025, Precision BioSciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements and exhibits, with no sp
• Precision BioSciences Files 8-K on Shareholder Vote Matters — Jun 3, 2025 Risk: low
  Precision BioSciences, Inc. filed an 8-K on May 28, 2025, to report on matters submitted to a vote of its security holders. The filing details the submission of
• Precision BioSciences Files 8-K on Financials — May 15, 2025 Risk: low
  Precision BioSciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures u
• Precision BioSciences Files 8-K — May 14, 2025 Risk: low
  Precision BioSciences, Inc. filed an 8-K on May 14, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing do
• 8-K Filing — Mar 7, 2025
• 8-K Filing — Jan 29, 2025
• Precision BioSciences Sells Gene Editing Business for $50M — Jan 8, 2025 Risk: medium
  Precision BioSciences, Inc. announced on January 6, 2025, that it has entered into a definitive agreement to sell its gene editing business to a third party. Th
• Precision BioSciences Sells Gene Editing Business — Oct 24, 2024 Risk: medium
  Precision BioSciences, Inc. announced on October 24, 2024, that it has entered into a definitive agreement to sell its gene editing business to an undisclosed b
• Precision BioSciences Appoints New CMO, Director — Sep 12, 2024 Risk: medium
  Precision BioSciences, Inc. announced on September 9, 2024, the appointment of Dr. Michael A. Caligiuri as Chief Medical Officer and the election of Dr. Sarah E
• Precision BioSciences Sells Gene Editing Business — Sep 3, 2024 Risk: medium
  Precision BioSciences, Inc. announced on September 3, 2024, that it has entered into a definitive agreement to sell its gene editing business to a third party.
• Precision BioSciences Reports Board & Executive Changes — Jun 10, 2024 Risk: medium
  On June 4, 2024, Precision BioSciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the
• Precision BioSciences Sells Gene Editing Unit to Syngenta for $100M — May 8, 2024 Risk: medium
  Precision BioSciences, Inc. announced on May 8, 2024, that it has entered into a definitive agreement to sell its gene editing business to Syngenta Group for $1
• Precision BioSciences Terminates Novartis Gene Therapy Deal — Apr 16, 2024 Risk: medium
  On April 11, 2024, Precision BioSciences, Inc. announced the termination of its collaboration and license agreement with Novartis Gene Therapies, Inc. This term
• Precision BioSciences Sells Gene Editing Unit to Syngenta for $100M — Mar 1, 2024 Risk: medium
  Precision BioSciences, Inc. announced on March 1, 2024, that it has entered into a definitive agreement to sell its gene editing business to Syngenta Group for
• Precision BioSciences Files Bylaw Amendments — Feb 13, 2024 Risk: medium
  Precision BioSciences, Inc. filed an 8-K on February 13, 2024, to report amendments to its Articles of Incorporation or Bylaws and to include Financial Statemen
• DTIL Files 8-K on Officer/Director Changes & Compensation — Jan 23, 2024
  Precision BioSciences, Inc. (DTIL) filed an 8-K on January 23, 2024, reporting that the earliest event occurred on January 22, 2024. This filing indicates a cur
• Precision BioSciences Confirms Nasdaq Listing & Common Stock Details — Jan 19, 2024
  Precision BioSciences, Inc. filed an 8-K on January 19, 2024, to report that it is a registrant with its Common Stock, par value $0.000005 per share, traded on
• Precision BioSciences Reports Material Agreement, Equity Sales — Jan 11, 2024
  Precision BioSciences, Inc. (DTIL) filed an 8-K on January 11, 2024, reporting an event on January 7, 2024, related to entering a material definitive agreement,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX